Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

GPCR Roundtable Participants

By Drug Discovery Trends Editor | February 2, 2009

Web Exclusive

Meet the scientists of Drug Discovery & Development magazine’s GPCR Roundtable.

Suresh PodaSuresh Poda (PhD, biochemistry), is a senior scientist at the HTS Center for Lundbeck in Paramus, N.J. The company’s research focuses on CNS disorders. While the primary targets are GPCRs—monoimmuno receptors and other GPCRs that are involved in neurotransmitter pathways—the company also studies ion channel and enzyme targets.

 

Charles A. LunnCharles A. Lunn (PhD, biochemistry), is a research fellow in New Lead Discovery at Schering-Plough Research Institute in Kenilworth, N.J. His group develops HTS assays. Targets include immunology and cardiovascular disease. Most of the GPCR targets investigated in recent years have utilized cell-based assays, looking at second messengers, as well as more primary readouts.

 

Richard EglenRichard Eglen (PhD, pharmacology), is president of Bio-discovery at PerkinElmer, Waltham, Mass. He has worked in drug discovery at GPCRs, as well as the development of technologies to screen compounds at GPCRs for central nervous system, cardiovascular, and metabolic disorders. His research has focused on muscarinic, serotonergic, and opioid receptors.


Filed Under: Drug Discovery

 

Related Articles Read More >

Chemical formula of psilocybin
Psychedelic pioneer Compass files for FDA approval as rivals close in
Insilico’s AI-designed TEAD inhibitor shrank tumors in 4 of 22 mesothelioma patients; randomized Phase 2a planned for 2027
If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE